BioCryst Pharmaceuticals, Inc.
BCRX
$6.83
-$0.50-6.82%
| Weiss Ratings | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.97 | |||
| Price History | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.77% | |||
| 30-Day Total Return | -17.61% | |||
| 60-Day Total Return | -15.16% | |||
| 90-Day Total Return | -10.13% | |||
| Year to Date Total Return | -12.77% | |||
| 1-Year Total Return | 48.48% | |||
| 2-Year Total Return | -19.93% | |||
| 3-Year Total Return | -57.92% | |||
| 5-Year Total Return | 233.17% | |||
| 52-Week High % Change | -28.11% | |||
| 52-Week Low % Change | 69.48% | |||
| Price | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.50 | |||
| 52-Week Low Price | $4.03 | |||
| 52-Week Low Price (Date) | Apr 25, 2024 | |||
| 52-Week High Price (Date) | Feb 20, 2025 | |||
| Valuation | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.43B | |||
| Enterprise Value | 1.95B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.43 | |||
| Earnings Per Share Growth | -63.59% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.14 | |||
| Price/Book (Q) | -2.99 | |||
| Enterprise Value/Revenue (TTM) | 4.32 | |||
| Price | $6.83 | |||
| Enterprise Value/EBITDA (TTM) | 4,153.02 | |||
| Enterprise Value/EBIT | -765.93 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 207.38M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 919 859 1302 | |||
| Address | 4505 Emperor Boulevard Durham, NC 27703 | |||
| Website | www.biocryst.com | |||
| Country | United States | |||
| Year Founded | 1986 | |||
| Profitability | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -0.56% | |||
| Profit Margin | -19.72% | |||
| Management Effectiveness | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -0.32% | |||
| Return on Equity | -- | |||
| Income Statement | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 450.71M | |||
| Total Revenue (TTM) | 450.71M | |||
| Revenue Per Share | $2.17 | |||
| Gross Profit (TTM) | 263.59M | |||
| EBITDA (TTM) | 469.00K | |||
| EBIT (TTM) | -2.54M | |||
| Net Income (TTM) | -88.88M | |||
| Net Income Avl. to Common (TTM) | -88.88M | |||
| Total Revenue Growth (Q YOY) | 40.83% | |||
| Earnings Growth (Q YOY) | 56.59% | |||
| EPS Diluted (TTM) | -0.43 | |||
| EPS Diluted Growth (Q YOY) | 58.02% | |||
| Balance Sheet | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 320.85M | |||
| Cash Per Share (Q) | $1.55 | |||
| Total Current Assets (Q) | 421.97M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -475.93M | |||
| Current Ratio (Q) | 2.631 | |||
| Book Value Per Share (Q) | -$2.28 | |||
| Total Assets (Q) | 490.42M | |||
| Total Current Liabilities (Q) | 160.38M | |||
| Total Debt (Q) | 841.42M | |||
| Total Liabilities (Q) | 966.35M | |||
| Total Common Equity (Q) | -475.93M | |||
| Cash Flow | BCRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 52.59M | |||
| Cash from Financing (TTM) | -5.76M | |||
| Net Change in Cash (TTM) | -6.12M | |||
| Levered Free Cash Flow (TTM) | 11.16M | |||
| Cash from Operations (TTM) | -52.02M | |||
